metricas
covid
Buscar en
Clínica e Investigación en Arteriosclerosis
Toda la web
Inicio Clínica e Investigación en Arteriosclerosis El fenotipo de lipoproteína(a): ¿un marcador genético de enfermedad coronaria...
Información de la revista
Vol. 16. Núm. 4.
Páginas 127-132 (enero 2004)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 16. Núm. 4.
Páginas 127-132 (enero 2004)
Acceso a texto completo
El fenotipo de lipoproteína(a): ¿un marcador genético de enfermedad coronaria?
Lipoprotein(a) phenotype: a genetic marker for coronary heart disease?
Visitas
3147
J.J. Gómez-Barradoa,
Autor para correspondencia
jjgbarrado@terra.es

Correspondencia: Plaza de Noruega, 7, 1.° A. 10005 Cáceres. España
, S. Turéganoa, J.C. García-Rubirab, J.M. Cruzc
a Servicio de Cardiología. Hospital San Pedro de Alcántara. Cáceres. España
b Servicio de Cardiología. Hospital Clínico San Carlos. Madrid. España
c Servicio de Cardiología. Hospital Universitario Virgen Macarena. Sevilla. España
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Objetivo

Estudiar la relación entre las concentraciones séricas de lipoproteína(a) y el fenotipo de apolipoproteína(a) en un grupo de varones con síndrome coronario agudo.

Pacientes y método

Se determinaron las concentraciones séricas de lipoproteína(a) y el fenotipo de apolipoproteína(a) a 22 varones de entre 30 y 80 años con síndrome coronario agudo,al ingreso y al mes de evolución.

Resultados

Los varones con un síndrome coronario agudo muestran una frecuencia elevada de fenotipos de apolipoproteína(a) de tamaño pequeño y concentraciones más elevadas de lipoproteína(a).

Conclusiones

El fenotipo de apolipoproteína(a) puede desempeñar un papel adicional en la etiología de la enfermedad arterial coronaria.

Palabras clave:
Lipoproteína(a)
Apolipoproteínas
Enfermedad coronaria
Objective

To study the relationship between the plasma concentrations of lipoprotein(a) and apolipoprotein(a) phenotype in a group of males with acute coronary syndromes.

Patients and method

Plasma lipoprotein(a) concentrations and apolipoprotein(a) phenotype were determined in twenty-two males aged thirty to eighty years with acute coronary syndrome on admission and at one month of follow-up.

Results

Patients with acute coronary syndrome showed a high frequency of small-sized apolipoprotein(a) phenotypes and higher lipoprotein(a) concentrations.

Conclusions

Apolipoprotein(a) phenotype may play an additional role in the etiology of coronary artery disease.

Key words:
Lipoprotein(a)
Apolipoproteins
Coronary heart disease
El Texto completo está disponible en PDF
Bibliografía
[1.]
G. Uterman.
The mysteries of lipoprotein(a).
Science, 246 (1989), pp. 904-910
[2.]
G. Utterman, H.J. Menzel, H.G. Kraft, H.C. Duba, H.G. Kemmler, C. Seiyz.
Lipoprotein(a) glycoprotein phenotypes. inheritance and relation to lp(a)-lipoprotein concentrations in plasma.
J Clin Invest, 80 (1987), pp. 458-465
[3.]
C. Lackner, J.C. Cohen, H. Hobbs.
Molecular definition of the extreme size polymorphism in apolipoprotein(a).
Hum Mol Gen, 2 (1993), pp. 933-940
[4.]
E. Boerwinkle, H.J. Menzel, H.G. Kraft.
Genetics of the quantitative lp(a) lipoprotein trait.
Hum Genet, 82 (1989), pp. 73-78
[5.]
G. Uterman, C. Duba, H.J. Menzel.
Genetics of the quantitative lp(a) lipoprotein trait. II: inherence of lp(a) glycoprotein phenotypes.
Hum Genet, 78 (1988), pp. 47-50
[6.]
E. Boerwinkle, C.C. Leffert, J. Lin, C. Lackner, G. Chiesa, H.H. Hobbs.
Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations.
J Clin Invest, 90 (1992), pp. 52-60
[7.]
M. Seed, F. Hoppichler, D. Reaveley, S. McCarthy, G.R. Thompson, E. Boerwinkle, et al.
Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia.
N Engl J Med, 322 (1990), pp. 1494-1499
[8.]
J.D. Kark, C. Sandholzer, Y. Friedlander, G. Uterman.
Plasma lp(a), apolipoprotein(a) isoforms and acute myocardial infarction in men and women: a case-control study in the jerusalem population.
Atherosclerosis, 98 (1993), pp. 139-151
[9.]
J.W. Gaubatz, R.C. Hoogeven, A.S. Hoffman, K.G. Ghazzaly, H.J. Pownall, J. Jr Guevara, et al.
Isolation, quantitation, and characterization of stable complex formed by lp(a) binding to triglyceride-rich lipoproteins.
J Lipid Res, 42 (2001), pp. 2058-2068
[10.]
G.M. Kostner, P. Avogaro, G. Cazzolato, E. Marth, G. Bittolo-Bon, G.B. Qunici.
Lipoprotein lp(a) and the risk of myocardial infarction.
Atherosclerosis, 38 (1981), pp. 51-61
[11.]
J. Jr Genest, J.L. Jenner, J.R. McNamara, J.M. Ordovas, S.R. Silberman, P.W.F. Wilson, et al.
Lipoprotein cholesterol, apolipoprotein a-i and b and lipoprotein(a) abnormalities in men with premature coronary artery disease.
J Am Coll Cardiol, 19 (1992), pp. 792-802
[12.]
G.C. Rhoads, G. Dahlen, K. Berg, E.N. Morton, A.L. Dannenberg.
Lp(a) lipoprotein as a risk factor for myocardial infarction.
JAMA, 256 (1986), pp. 2540-2544
[13.]
M. Bihari-Varga, G. Kostner, A. Czinner.
Lp(a) and the risk of coronary heart disease.
Eur J Epidemiol, 8 (1992), pp. 33-35
[14.]
J.W. McLean, J.E. Tomlinson, W.J. Kuang.
CDNA sequence of human apolipoprotein(a) is homologous to plasminogen.
Nature, 330 (1987), pp. 132-137
[15.]
K.A. Hajjar, D. Gavish, J.L. Breslow, R.L. Nachman.
Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis.
Nature, 339 (1989), pp. 303-305
[16.]
L.A. Miles, G.A. Fless, F.G. Levin, A.M. Scanu, E.F. Flow.
A potential basis for the trombotic risk associated with lipoprotein(a).
Nature, 339 (1989), pp. 301-303
[17.]
D.I. Simon, G.M. Fless, A.M. Scanu.
Tissue type plasminogen activator binds to and is inhibited by surface-bound lp(a) and LDL.
Biochemistry, 30 (1991), pp. 6671-6677
[18.]
J.M. Edelberg, C.F. Reilly, S.V. Pizzo.
The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. the effects of fibrinogen, heparin vitronectin and lipoprotein(a).
J Biol Chem, 266 (1991), pp. 7488-7493
[19.]
M.J. Chapman, T. Huby, F. Nigon, J. Thillet.
Lipoprotein(a): implication in atherothrombosis.
Atherosclerosis, 110 (1994), pp. 69-75
[20.]
A.M. Scanu, G.M. Fless.
Lp(a) heterogeneity and biological relevance.
J Clin Invest, 85 (1990), pp. 1709-1715
[21.]
J.C. Cohen, G. Chiesa, H.H. Hobbs.
Sequence polymorphisms in the apolipoprotein(a) gene. evidence for dissociation between apolipoprotein(a) size and plasma lipoprotein(a) levels.
J Clin Invest, 91 (1993), pp. 1630-1636
[22.]
J. Pedro-Botet, M. Sentí, J. Rubiés-Prat, T. Auguet, J. Marrugat.
Relación entre concentración sérica de lipoproteína(a), polimorfismo genético de la apolipoproteína(a) e historia familiar de arteriosclerosis.
Clin Invest Arterioscl, 7 (1995), pp. 144-149
[23.]
C. Sandholzer, D.M. Hallman, M. Saha, G. Sigurdsson, C. Lackner, A. Csaszar, et al.
Effects of the apolipoprotein(a) size polymorphism on the lp(a) concentration in 7 ethnic groups.
Hum Genet, 86 (1991), pp. 607-614
[24.]
S. Islam, B. Gutin, C. Smith, F. Treiber, M.I. Kamboh.
Association of apolipoprotein(a) phenotypes in children with family history of premature coronary artery disease.
Arterioscler Thromb, 14 (1994), pp. 1609-1616
[25.]
S. Martín, J. Pedro-Botet, J. Joven, J.M. Simó, M.G. Ladona, M. Pavesa, et al.
Heterozygous apolipoprotein(a) status and protein expression as a risk factor for premature coronary heart disease.
J Lab Clin Med, 139 (2002), pp. 181-187
[26.]
R. Carmena, S. Lussier-Cacan, M. Roy, A. Minnich, A. Lirgenhel, F. Kronenberg, et al.
Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect.
Arteriocler Thromb, 16 (1996), pp. 129-136
[27.]
M. Parlavecchia, A. Pancaldi, R. Taramelli, P. Valsania, L. Galli, G. Pozza, et al.
Evidence that apolipoprotein(a) phenotype is a risk factor for coronary artery disease in men < 55 years of age.
Am J Cardiol, 74 (1994), pp. 346-351
Copyright © 2003. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos